Cargando…

Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling

OBJECTIVE: First-line (1L) maintenance avelumab prolonged overall survival (OS) in patients with advanced urothelial carcinoma (aUC) in JAVELIN Bladder 100. OS was measured from maintenance initiation in patients with disease control following 1L platinum-based therapy (PBT). The OS impact of mainte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galsky, Matthew D, Wirtz, Heidi S, Bloudek, Brian, Hepp, Zsolt, Farrar, Mallory, Timmons, Jack, Lenero, Enrique, Powles, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290854/ https://www.ncbi.nlm.nih.gov/pubmed/37366420 http://dx.doi.org/10.2147/CLEP.S409791

Ejemplares similares

Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology
por: Bloudek, Brian, et al.
Publicado: (2022)

Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)
por: Bloudek, Lisa, et al.
Publicado: (2023)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy
por: Alqaisi, Husam A., et al.
Publicado: (2022)

Systematic Review of Migraine Prophylaxis Adherence and Persistence
por: Hepp, Zsolt, et al.
Publicado: (2014)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
por: Liu, Xiaoyan, et al.
Publicado: (2022)

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study
por: Kim, Hyunho, et al.
Publicado: (2020)

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer
por: Uchida, Hideaki, et al.
Publicado: (2023)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

HER2 expression in urothelial carcinoma, a systematic literature review
por: Scherrer, Emilie, et al.
Publicado: (2022)

Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada
por: Alimohamed, Nimira, et al.
Publicado: (2022)

Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
por: Abe, T, et al.
Publicado: (2019)

Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy
por: Huang, Hui-Shan, et al.
Publicado: (2018)

Benchmarking of the maintenance cost in HEPT Centers
por: Béjar-Alonso, Isabel, et al.
Publicado: (2002)

Erratum to: Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
por: Abe, T, et al.
Publicado: (2020)

A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent
por: Sharma, Padmanee, et al.
Publicado: (2015)

ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer
por: Fulton, Ben, et al.
Publicado: (2020)

Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
por: Tan, David SP, et al.
Publicado: (2021)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
por: Powles, Thomas, et al.
Publicado: (2023)

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
por: Lin, Liping, et al.
Publicado: (2016)

Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis
por: Hepp, Zsolt, et al.
Publicado: (2021)

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2015)

Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)
por: Misra, Ankit
Publicado: (2021)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

The role of switch maintenance therapy in urothelial cancers
por: Yu, Eun-mi, et al.
Publicado: (2023)

Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results
por: Ciardiello, Fortunato, et al.
Publicado: (2023)

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
por: Grivas, P., et al.
Publicado: (2023)

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
por: de Wit, Ronald, et al.
Publicado: (2022)

A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma
por: Crabb, Simon J., et al.
Publicado: (2023)

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy
por: Houédé, N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v2jhd8jv6hdq1a2qpap4dvc00d